|
Hypertension without complications
|
44.4
|
87.1
|
|
Beta-blockers (ATC code C07)
| |
49.8
|
|
ACE inhibitors (ATC codes C09AA, C09B)
| |
37.5
|
|
Angiotensin-I-antagonists (ATC codes C09CA, C09D)
| |
34.8
|
|
Diuretic drugs (ATC code C03)
| |
22.7
|
|
Hypertension with complications
|
7.2
|
98.3
|
|
Beta-blockers (ATC code C07)
| |
66.0
|
|
ACE inhibitors (ATC codes C09AA, C09B)
| |
37.5
|
|
Angiotensin-I-antagonists (ATC codes C09CA, C09D)
| |
49.2
|
|
Diuretic drugs (ATC code C03)
| |
45.5
|
|
Depression
|
25.6
|
46.7
|
|
Anti-depressants (ATC code N06A)
| |
46.7
|
|
Chronic pulmonary disease
|
23.4
|
46.9
|
|
LABA (ATC codes R03AC, R03AK, R03AL)
| |
41.0
|
|
LAMA (ATC code R03BB)
| |
9.6
|
|
Inhaled corticosteroids (ATC code R03BA)
| |
13.2
|
|
Diabetes with complications
|
8.7
|
77.4
|
|
Insulin (ATC code A10A)
| |
32.6
|
|
Oral hypoglycaemics (ATC code A10B)
| |
60.1
|
|
Diabetes without complications
|
7.3
|
44.4
|
|
Insulin (ATC code A10A)
| |
12.4
|
|
Oral hypoglycaemics (ATC code A10B)
| |
38.6
|
|
Cardiac arrhythmias
|
14.2
|
68.5
|
|
Beta-blockers (ATC code C07)
| |
65.9
|
|
Digitalis glycosides (ATC code C01AA)
| |
5.7
|
|
Anti-arrhythmic drugs (ATC code C01BD)
| |
3.8
|
|
Peripheral vascular disorders
|
8.7
|
63.0
|
|
Antiplatelet drugs (ATC code B01AC)
| |
26.5
|
|
Heparin (−derivates) (ATC code B01AA)
| |
12.3
|
|
Vitamin K antagonists (ATC code B01AB)
| |
11.4
|
|
Statins (ATC code C10AA)
| |
44.2
|
|
Valvular disease
|
8.1
|
73.7
|
|
Beta-blockers (ATC code C07)
| |
62.0
|
|
ACE inhibitors (ATC codes C09AA, C09B)
| |
35.0
|
|
Diuretic drugs (ATC code C03)
| |
28.5
|
|
Congestive heart failure
|
5.7
|
92.5
|
|
Beta-blockers (ATC code C07)
| |
69.2
|
|
ACE inhibitors (ATC codes C09AA, C09B)
| |
40.2
|
|
Angiotensin-I-antagonists (ATC codes C09CA, C09D)
| |
36.9
|
|
Digitalis glycosides (ATC code C01AA)
| |
9.4
|
|
Diuretic drugs (ATC code C03)
| |
53.0
|
|
Fibromyalgia
|
4.4
|
19.7
|
|
Duloxetine (ATC code N06AX21)
| |
5.0
|
|
Pregabalin (ATC code N03AX16)
| |
9.5
|
|
Gabapentin (ATC code N03AX12)
| |
5.2
|
